头颈癌患者EORTC量表映射至EQ-5D-5L与HUI-3效用指数
本研究纳入209例头颈癌门诊患者,同时完成EORTC QLQ-C30与QLQ-H&N35、EQ-5D-5L及HUI-3量表,采用普通最小二乘回归和两部模型构建映射函数。该映射算法有助于将EORTC评分转换为健康效用值。
要点
- EQ-5D-5L模型在亚组分析中可区分部分疾病严重程度临床指标。
核心结论
- EORTC至EQ-5D-5L的映射算法具有良好预测效度,可将EORTC评分转换为头颈癌患者的健康效用值。
研究设计与样本
- 纳入209例头颈癌门诊患者,同步收集EORTC QLQ-C30与QLQ-H&N35、EQ-5D-5L及HUI-3数据。
- 采用普通最小二乘回归和两部模型将EORTC结果映射至EQ-5D-5L与HUI-3评分。
主要发现
- 亚组分析显示EQ-5D-5L模型能够区分某些疾病严重程度的临床指标。
临床怎么用
- 研究者可利用EORTC至EQ-5D-5L映射算法,将头颈癌患者的EORTC评分转换为健康效用值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We sought to develop mapping functions that use EORTC responses to approximate health utility (HU) scores for patients with head and neck cancer (HNC). METHODS: In total, 209 outpatients with HNC completed the EORTC QLQ-C30 & QLQ-H&N35 (EORTC), EQ-5D-5L and the HUI-3. Results of the EORTC were mapped onto both EQ-5D-5L and HUI-3 scores using ordinary least squares regression and two-part models. RESULTS: The OLS model mapping EORTC onto the EQ-5D-5L performed best (adjusted R2 = .75, 10-fold cross-validation RMSE = 0.064, MAE 0.050). The HUI-3 model mapping onto EORTC through OLS was more limited (adjusted R2 = .5746, 10-fold cross cross-validation RMSE = 0.168, MAE 0.080). The EQ-5D-5L model was able to discriminate between certain clinical indices of disease severity on subgroup analysis. CONCLUSION: The EORTC to EQ-5D-5L mapping algorithm has good predictive validity and may enable researchers to translate EORTC scores into HU scores for head and neck patients with cancer.
引用
- Noel CW, Stephens RF, Su JS, et al. Mapping the EORTC QLQ-C30 and QLQ-H&N35, onto EQ-5D-5L and HUI-3 indices in patients with head and neck cancer. Head Neck. 2020. PMID: 32333829. doi:10.1002/hed.26181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。